CTC researchers and their collaborators have a strong record of published research in prestigious international journals. Recent journal articles are listed here.
Follow the link to find specific articles back to 2005.
Search for articles
Adams EJ, Cox JM, Adamson BJ, Schofield DJ. Truncated careers in nuclear medicine technology: increased job control may improve retention. Australian Health Review 2011; 35 (2) :124–129.
Ananda S, Nowak AK, Cher L, Dowling A, Brown C, Simes J, Rosenthal MA, and for the Cooperative Trials Group for Neuro-Oncology (COGNO). Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. Journal of Clinical Neuroscience 2011; 18 (11) :1444–1448.
Askie L, Brocklehurst P, Darlow B, Finer N, Schmidt B, Tarnow-Mordi W, NeOProM Collaborative Group. NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. BMC Pediatrics 2011; 11 (1) :6.
Askie LM. Australian New Zealand Clinical Trials Registry: history and growth. Journal of Evidence-Based Medicine 2011; 4:185-187.
Askie LM, Ballard RA, Cutter GR, Dani C, Elbourne D, Field D, Hascoet JM, Hibbs AM, Kinsella JP, Mercier JC, Rich W, Schreiber MD, Wongsiridej PS, Subhedar NV, Van Meurs KP, Voysey M, Barrington K, Ehrenkranz RA, Finer NN, on behalf of the Meta-analysis of Preterm Patients on Inhaled Nitric Oxide (MAPPiNO) Collaboration. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics 2011; 128 (4) :729–739.
Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck D-A, Whittom R, Langer C, O'Callaghan CJ. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology 2011; 22 (1) :118-126.
Bagia M, Nowak AK. Novel targeted therapies and vaccination strategies for mesothelioma. Current Treatment Options in Oncology 2011; 12 (2) :149–162.
Baigent C, Emberson J, Blackwell L, Keech A, Collins R, for the Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: authors' reply [letter]. Lancet 2011; 377 (9767) :715.
Bell KJL, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ 2011; 342:d12.
Blinman P, McLachlan SA, Nowak AK, Duric VM, Brown C, Wright G, Millward M, Fong K, Stockler MR. Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?. Lung Cancer 2011; 72 (2) :213–218.
Callander EJ, Schofield DJ. Emergency department workforce models: what the literature can tell us. Emergency Medicine Australasia 2011; 23 (1) :84–94.
Callander EJ, Schofield DJ, Shrestha RN. Freedom poverty: A new tool to identify the multiple disadvantages affecting those with CVD. International Journal of Cardiology 2011;
Cameron A, Barbour A, Wayte N, Akhurst T. Biomarkers in oesophagogastric cancers. Cancer Forum 2011; 35 (3) :166-172.
Cameron A, Sjoquist KM, Zalcberg JR. Overview of controversies in oesophagogastric cancer. Cancer Forum 2011; 35 (3) :139-141.
Changsirivathanathamrong D, Wang Y, Rajbhandari D, Maghzal GJ, Mak WM, Woolfe C, Duflou J, Gebski V, Dos Remedios CG, Celermajer DS, Stocker R. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Critical Care Medicine 2011; 39 (12) :2678-2683.
Chen JY, Hruby G, Stockler MR, Patanjali N, Bucci J, Perez G, Loadsman JA, Sheehan E. Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. Brachytherapy 2011; 10 (6) :454-460.
Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbut NC, Buck M, Lowenthal RM, Boland A, Gebski V, Zalcberg J, Simes RJ,, on behalf of the Australasian Gastro-Intestinal Trials Group. Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis.. European Journal of Cancer 2011; 47 (12) :1826-1836.
Coburn N, Beldham-Collins R, Westling J, Trovato J, Gebski V. Evaluation of flexible and rigid (class solution) radiation therapy conformal prostate planning protocols. Medical Dosimetry 2011;
Cox KM, Goel S, O'Connell RL, Boyer M, Beale PJ, Simes RJ, Stockler MR. A randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal 2011; 41 (2) :172-178.
Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC, on behalf of the FIELD Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54 (2) :280–290.
de Boer SPM, Barnes EH, Westerhout CM, Simes RJ, Granger CB, Kastrati A, Widimsky P, de Boer MJ, Zijlstra F, Boersma E. High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration. American Heart Journal 2011; 161 (3) :500-507.e1.
Dear R, Barratt A, Askie L, McGeechan K, Arora S, Crossing S, Currow D, Tattersall M. Adding value to clinical trial registries: insights from Australian Cancer Trials Online, a website for consumers. Clinical Trials 2011; 8 (1) :70-76.
Dear RF, Barratt AL, McGeechan K, Askie L, Simes J, Tattersall MHN. Landscape of cancer clinical trials in Australia: using trial registries to guide future research. Medical Journal of Australia 2011; 194 (8) :387–391.
Dietz H, Bernardo M, Kirby A, Shek K. Minimal criteria for the diagnosis of avulsion of the puborectalis muscle by tomographic ultrasound. International Urogynecology Journal 2011; 22 (6) :699-704.
Dietz HP, Franco AV, Shek KL, Kirby A. Avulsion injury and levator hiatal ballooning: two independent risk factors for prolapse? An observational study. Acta Obstetricia et Gynecologica Scandinavica 2011;
Dobson RJ, Barnes EH, Tyrrell KL, Hosking BC, Larsen JWA, Besier RB, Love S, Rolfe P.F, Bailey JN. A multi-species model to assess the effect of refugia on worm control and anthelmintic resistance in sheep grazing systems. Australian Veterinary Journal 2011; 89 (6) :200-208.
Doyle L, Crowther C, Middleton P, Voysey M, Marret S, Rouse D. Antenatal magnesium sulphate to prevent cerebral palsy in very preterm infants [letter]. British Journal of Obstetrics and Gynaecology 2011; 118 (7) :891-892.
Drury P, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis T, Pardy C, Colman P, Keech A. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011; 54 (1) :32-43.
Ellingson K, Muder R, Jain R, Kleinbaum D, Feng PJI, Cunningham C, Squier C, Lloyd J, Edwards J, Gebski V, Jernigan J. Sustained reduction in the clinical incidence of methicillin-resistant staphylococcus aureus colonization or infection associated with a multifaceted infection control intervention. Infection Control and Hospital Epidemiology 2011; 32 (1) :1-8.
Farrar D, Duley L Burls A, Dorling J, Embleton N, McGuire W, Oddie S, Simes J, Tarnow-Mordi W, Thornton J, Tuffnell D, Yoxall B. Rushing to clamp umbilical cord. More evidence is needed to inform practice [letter]. BMJ 2011; 342:d122.
Fogarty G, Morton R, Vardy J, Nowak A, Mandel C, Forder P, Hong A, Hruby G, Burmeister B, Shivalingam B, Dhillon H, Thompson J. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients: a randomised phase III trial. BMC Cancer 2011; 11 (1) :142.
Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GCE, on behalf of the Gynecologic Cancer InterGroup. Clinical trials in recurrent ovarian cancer. International Journal of Gynecological Cancer 2011; 21 (4) :771-775.
Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D'Amico M, Decensi A, Bruzzi P. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. Journal of Clinical Oncology 2011; 29 (16) :2144–2149.
Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of Oncology 2011;
Goel S, Simes RJ, Beith JM. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia-Pacific Journal of Clinical Oncology 2011; 7 (3) :276–280.
Goldstein D Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IWT, Hruby G, Horvath L, Bydder S, Undercill C, Harvey J, Gebski VJ, on behalf of the Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer 2011;
Goldstein D, Gainford M, Brown C, Tebbutt N, Ackland S, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, Gebski V, Miller D, Shannon J. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology 2011; 67 (3) :519-525.
Hayes AJ, Clarke PM, Voysey M, Keech A. Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes. Medical Decision Making 2011; 31 (4) :559–570.
Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study. Lancet 2011; 377 (9764) :469-476.
Howle JR, Hughes TM, Gebski V, Veness MJ. Merkel cell carcinoma: an Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. Journal of the American Academy of Dermatology 2011;
Hruby G, Chen JY, Bucci J, Loadsman JA, Perry P, Stockler MR. Patients' experiences of high-dose rate brachytherapy boost for prostate cancer using an inpatient protocol. Brachytherapy 2011; 10 (5) :395-400.
INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. New England Journal of Medicine 2011; 365:1201–1211.
Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, Reinthaller A, Vergote I, Ferrandina G, Dell'anna T, Huober J, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecologic Oncology 2011; 122 (2) :226-232.
Kao SCH, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ., Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. Journal of Thoracic Oncology 2011; 6 (11) :1923-1929.
Kiely BE, Hossack LK, Shadbolt CL, Davis A, Cassumbhoy R, Moodie K, Antill Y, Mitchell G. Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer. ANZ Journal of Surgery 2011; 81 (10) :688-693.
Kiely BE, Soon YY, Tattersall MHN, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. Journal of Clinical Oncology 2011; 29 (4) :456-463.
Kiely BE, Stockler MR, Tattersall MHN. Thinking and talking about life expectancy in incurable cancer. Seminars in Oncology 2011; 38 (3) :380-385.
Kiely BE, Wilcken NRC, Stockler MR. Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology 2011; 29 (9) :1092–1093.
Kilbreath S, Refshauge KM, Beith J, Ward L, Sawkins K, Paterson R, Clifton-Bligh P, Sambrook PN, Simpson JM, Nery L. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial. Contemporary Clinical Trials 2011; 32 (5) :704-709.
Ko H, Turner T, Finnigan M. Systematic review of safety checklists for use by medical care teams in acute hospital settings - limited evidence of effectiveness. BMC Health Services Research 2011; 11 (1) :211.
Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Sambia G, Varsellona N, Brown C, Pujade-Lauraine E, on behalf of Gynecologic Cancer Intergroup. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Annals of Oncology 2011; 22 (11) :2417-2423.
Lee C, Hudson M, Stockler M, Coates A, Ackland S, Gebski V, Lord S, Friedlander M, Boyle F, Simes R. A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment 2011; 129 (2) :467–476.
Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Raza Mirza M, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. Journal of the National Cancer Institute 2011; 103 (17) :338-1342.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer 2011; 105 (3) :360–365.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A., Bourgeois H, Hogberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer 2011; 105 (8) :1144-1150.
Lord SJ, Staub LP, Bossuyt PM, Irwig LM. Target practice: choosing target conditions for test accuracy studies that are relevant to clinical practice. BMJ 2011; 343:d4684.
Luckett T, Goldstein D, Butow PN, Gebski V, Aldridge LJ, McGrane J, Ng W, King MT. Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. Lancet Oncology 2011; 12 (13) :1240-1248.
Marschner IC, Gillett AC. Relative risk regression: reliable and flexible methods for log-binomial models. Biostatistics 2011;
McIntyre S Badawi N, Brown C, Blair E. Population case-control study of cerebral palsy: neonatal predictors for low-risk term singletons. Pediatrics 2011; 127 (3) :E667–E673.
Menzies SW, Stevenson ML, Altamura D, Byth K. Variables predicting change in benign melanocytic nevi undergoing short-term dermoscopic imaging. Archives of Dermatology 2011; 147 (6) :655-659.
Mohamed N., Eviston D. P., Quinton A. E., Benzie R. J., Kirby A. C., Peek M. J., Nanan R. K. Smaller fetal thymuses in pre-eclampsia: a prospective cross-sectional study. Ultrasound in Obstetrics & Gynecology 2011; 37 (4) :410-415.
Murali R, Zannino D, Synnott M, McCarthy SW, Thompson JF, Scolyer RA. Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. Histopathology 2011; 58 (6) :886–895.
Nicklin J, Janda M, Gebski V, Jobling T, Land R, Manolitsas T, McCartney A, Nascimento M, Perrin L, Baker J, Obermair A, for the LACE trial investigators. The utility of serum CA-125 in predicting extra-uterine disease in apparent early stage endometrial cancer. International Journal of Cancer 2011;
Noushi F, Spillane AJ, Uren RF, Gebski V. Internal mammary lymph node metastasis in breast cancer: Predictive models to assist with prognostic influence. Breast 2011; 20 (3) :278–283.
Ooi WL, Stockler M, Hayne D. Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC Genito-Urinary Group randomized phase 2 trial (30993). Eur Urol 2011;59:438-46 [letter]. European Urology 2011; 60 (1) :e1.
Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. Journal of Clinical Oncology 2011; 29 (19) :2675–2682.
Price TJ, Zannino D, Wilson K, Simes J, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Annals of Oncology 2011;
Savdie R Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL, Kench JG. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU International 2011;
Schofield D, Kelly S, Shrestha R, Passey M, Callander E, Percival R. The long term financial impacts of CVD: living standards in retirement. International Journal of Cardiology 2011;
Schofield D, Passey M, Percival R, Shrestha R, Callander E, Kelly S. Retiring early with cardiovascular disease—impact on individual's financial assets [letter]. International Journal of Cardiology 2011; 146 (1) :125-126.
Schofield D, Shrestha R, Percival R, Passey M, Callander E, Kelly S. The personal and national costs of CVD: Impacts on income, taxes, government support payments and GDP due to lost labour force participation. International Journal of Cardiology 2011;
Schofield D, Shrestha R, Percival R, Passey M, Callander E, Kelly S. The personal and national costs of mental health conditions: impacts on income, taxes, government support payments due to lost labour force participation. BMC Psychiatry 2011; 11 (1) :72.
Schofield DJ, Callander EJ, Shrestha RN, Percival R, Kelly SJ, Passey ME. Labour force participation and the influence of having CVD on income poverty of older workers. International Journal of Cardiology 2011;
Schofield DJ, Kelly SJ, Shrestha RN, Callander EJ, Percival R, Passey ME. How depression and other mental health problems can affect future living standards of those out of the labour force. Aging & Mental Health 2011; 15 (5) :654–662.
Schofield DJ, Meachem S, West C, Kavallaris M, Callander EJ. A crisis in the making? Education, ageing populations and the future of the medical research workforce. Medical Education 2011; 45 (2) :200-207.
Schofield DJ, Shrestha RN, Percival R, Callander EJ, Kelly SJ, Passey M. Early retirement and the financial assets of individuals with back problems. European Spine Journal 2011; 20 (5) :731–736.
Schofield DJ, Shrestha RN, Percival R, Kelly SJ, Passey ME, Callander EJ. Quantifying the effect of early retirement on the wealth of individuals with depression or other mental illness. British Journal of Psychiatry 2011; 198 (2) :123-128.
Schofield DJ, Shrestha RN, Percival R, Passey ME, Kelly SJ, Callander EJ. Economic impacts of illness in older workers: Quantifying the impact of illness on income, tax revenue and government spending. BMC Public Health 2011; 11 (1) :418.
Scott R, Donoghoe M, Watts GF, O’Brien R, Pardy C, Taskinen MR, Davis TME, Colman PG, Manning P, Fulcher G, Keech AC, on behalf of the FIELD study investigators. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology 2011; 10:102.
Simes RJ. Inspirations and influences for a life in clinical trials. Cancer Forum 2011; 35 (1) :48–50.
Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ., Barbour A, Gebski V, and for the Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology 2011; 12 (7 ) :681–692.
Sjoquist KM, Martyn J, Edmondson RJ, Friedlander ML. The role of hormonal therapy in gynecological cancers—current status and future directions. International Journal of Gynecological Cancer 2011; 21 (7) :1328–1333.
Stansby G, Mister R, Fowkes G, Roughton M, Nugara F, Brittenden J, Bradbury A, Ashley S, Shearman C, Hannon R, Flather M, PREPARED (Prospective Registry and Evaluation of Peripheral Arterial Risks Events and Distribution) Investigators. High risk of peripheral arterial disease in the United Kingdom: 2-year results of a prospective registry. Angiology 2011; 62 (2) :111–118.
Staub LP, Barz T, Melloh M, Lord SJ, Chatfield M, Bossuyt PM. Clinical validation study to measure the performance of the nerve root sedimentation sign for the diagnosis of lumbar spinal stenosis. Contemporary Clinical Trials 2011; 32 (3) :470–474.
Stenson B, Brocklehurst P, Tarnow-Mordi W, for the UK and Australian and New Zealand BOOST II trials. Increased 36-week survival with high oxygen saturation target in extremely preterm infants [letter]. New England Journal of Medicine 2011; 364:1680-1682.
Stevenson J, Brodaty H, Boyce P, Byth K. Personality disorder comorbidity and outcome: comparison of three age groups. Australian and New Zealand Journal of Psychiatry 2011; 45 (9) :771-779.
Stockler M. Quality of life and targeted treatment for metastatic renal cell carcinoma. Oncologist 2011; 16 (8) :1070-1071.
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. Journal of Clinical Oncology 2011;
Sullivan D, Forder P, Simes J, Whiting M, Kritharides L, Merrifield A, Donoghoe M, Colman PG, Graham N, Haapamäki H, Keech A, for the FIELD Study Investigators. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice 2011; 94 (2) :284-290.
Sullivan TR, Duque G, Keech AC, Herrmann M. An old friend in a new light: the role of osteocalcin in energy metabolism. Cardiovascular Therapeutics 2011;
Suttie CF, Hong A, Stalley P, Veillard AS, Tattersall MH. Does chemotherapy shorten the latency interval of radiation-induced sarcomas?. Clinical Oncology (Royal College of Radiologists). 2011;
Tarnow-Mordi W, Kumar P, Kler N. Neonatal trials need thousands, not hundreds, to change global practice [letter]. Acta Paediatrica 2011; 100 (3) :330-333.
Tarnow-Mordi W, Kumar P, Kler N. Need for larger trials in pediatric critical care and neonatal medicine [letter]. Acta Paediatrica 2011; 100 (5) :637.
Tarnow-Mordi WO, Evans NJ, Lui K, Darlow B, Advisory Committee of the Australian and New Zealand Neonatal Network. Risk of brain damage in babies from naphthalene in mothballs: call to consider a national ban [letter]. Medical Journal of Australia 2011; 194 (3) :150.
Tarnow-Mordi WO, Wilkinson D, Trivedi A. Necrotizing enterocolitis [letter]. New England Journal of Medicine 2011; 364 (19) :1877–1878.
Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ, on behalf of the Australasian Gastro-Intestinal Trials Group. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology 2011; 22 (8) :1834–1838.
Trinkaus ME, Sayed S, Gakinya SM, Moloo Z, Hanna W, Rahim Y. Triple negative and basal-like breast cancer in East Africa. Breast Journal 2011; 17 (4) :438–440.
Urwyler N, Staub E, Staub LP, Daetwyler K, Fluri S, Sollberger T, Theiler L, Greif R. Point-of-care prothrombin time testing in paediatric intensive care: an observational study of the ease of use of two devices. European Journal of Anaesthesiology 2011;
Wang JT, Palme CE, Morgan GJ, Gebski V, Wang AY, Veness MJ. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head & Neck 2011;
Yetukuri L, Huopaniemi I, Koivuniemi A, Maranghi M, Hiukka A, Nygren H, Kaski S, Taskinen MR, Vattulainen I, Jauhiainen M, Oreši. High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS One 2011; 6 (8) :e23589.
